-
Mashup Score: 0
Targeted degradation of EP300 with a novel PROTAC agent in neuroblastoma cells was found to cause widespread loss of gene expression and cell death in vitro and in vivo.
Source: aacrjournals.orgCategories: General Medicine News, Oncologists1Tweet
-
Mashup Score: 27Rally Foundation Awards $5M for a Record Number of Grants to 74 Childhood Cancer Researchers - 1 month(s) ago
This year, 51 researchers across 31 institutions worldwide will receive a total of $3.4 million in grants from Rally Foundation for Childhood Cancer Research.
Source: rallyfoundation.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 265 Questions for Noha Shendy, PhD - 5 month(s) ago
Learn why postdoctoral researcher Noha Shendy, PhD, chose to train at St. Jude, identifying new treatments for resistant or aggressive childhood cancers.
Source: blogs.stjude.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 27A CRISPR-drug perturbational map for identifying compounds to combine with commonly used chemotherapeutics - 6 month(s) ago
Combination chemotherapy is crucial for successfully treating cancer. However, the enormous number of possible drug combinations means discovering safe and effective combinations remains a significant challenge. To improve this process, we conduct large-scale targeted CRISPR knockout screens in drug-treated cells, creating a genetic map of druggable genes that sensitize cells to commonly used…
Source: www.nature.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 4Sr Researcher or Lead Researcher - Pediatric Oncology - Durbin Lab - 6 month(s) ago
The Senior Researcher performs a variety of basic laboratory research tasks determined by the field and scope of the particular research project/study, whereas the Lead Researcher performs a variety of moderately complex research tasks determined by the field and scope of the particular research project/study. Overview: We are seeking a Senior or Lead Researcher to join the lab of Dr. Adam Durbin in the Department of Oncology at St. Jude Children’s Research Hospital. With advances in functional genomics, the role of epigenetic enzymes and transcription factor complexes in driving cell lineage and cancer pathogenesis has come to the forefront. These represent new approaches to controlling high-risk childhood solid tumors, such as neuroblastoma. These processes are made more complex by the presence of intratumoral heterogeneity – the presence of cells in distinct states, within a complex primary tumor (Cell Reports Medicine 2022). Understanding the basic principles of how these cells int
Source: stjude.wd1.myworkdayjobs.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Genome-wide mapping of cancer dependency genes and genetic modifiers of chemotherapy in high-risk hepatoblastoma - 10 month(s) ago
A lack of relevant genetic models and cell lines hampers our understanding of hepatoblastoma pathogenesis and the development of new therapies for this neoplasm. Here, we report an improved MYC-driven hepatoblastoma-like murine model that recapitulates the pathological features of embryonal type of hepatoblastoma, with transcriptomics resembling the high-risk gene signatures of the human disease….
Source: www.nature.comCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0JCI - Genetic predisposition to neuroblastoma results from a regulatory polymorphism that promotes the adrenergic cell state - 12 month(s) ago
Abstract Childhood neuroblastomas exhibit plasticity between an undifferentiated neural crest–like mesenchymal cell state and a more differentiated sympathetic adrenergic cell state. These cell states are governed by autoregulatory transcriptional loops called core regulatory circuitries (CRCs), which drive the early development of sympathetic neuronal progenitors from migratory neural crest…
Source: www.jci.orgCategories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 3Postdoctoral Research Associate - Oncology in Memphis, Tennessee | St. Jude Children's Research Hospital - 2 year(s) ago
postdoc is hiring a Postdoctoral Research Associate – Oncology in Memphis, Tennessee. Review all of the job details and apply today!
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 0Senior or Lead Researcher in Oncology - Dr. Durbin's Lab in Memphis, Tennessee | St. Jude Children's Research Hospital - 2 year(s) ago
St. Jude Careers is hiring a Senior or Lead Researcher in Oncology – Dr. Durbin’s Lab in Memphis, Tennessee. Review all of the job details and apply today!
Categories: Hem/Oncs, Latest HeadlinesTweet
-
Mashup Score: 6Intrinsic transcriptional heterogeneity in neuroblastoma guides mechanistic and therapeutic insights - 2 year(s) ago
Evidence has implic ated intratumoral heterogeneity as a driver of resistance to cancer therapies. Shendy et al. review how intratumoral heterogeneity is controlled by flexible transcriptional circuitries in the pediatric high-risk malignancy neuroblastoma. They highlight mechanisms that maintain heterogeneity, providing areas for potential therapeutic interventions focusing on regulation of the…
Source: Cell Reports MedicineCategories: Hem/Oncs, Latest HeadlinesTweet
Previously, by studying these proteins, we identified that targeting these proteins in different ways might have different responses in cancer cells, including cell cycle arrest or apoptosis. See: https://t.co/aY8lyTZZq1